Drug Trial Radar · NCT04046224
Dose-Ranging Study of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy in Subjects With Fabry Disease (STAAR)
Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
36
Actual
Start
Jul 23, 2019
Primary completion
Apr 10, 2025
Study completion Apr 10, 2025
Sponsor
- Lead sponsor
- Sangamo TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Aug 6, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is the first in human treatment with ST-920, an adeno-associated virus (AAV2/6) vector encoding the complementary deoxyribonucleic acid (cDNA) for human a-Gal A. The purpose of this study is to evaluate the safety and tolerability of ascending doses of ST-920. ST-920 aims to provide stable, long-term production of α-Gal A at therapeutic levels in subjects with Fabry disease. The constant production of α-Gal A in humans should, importantly, enable reduction and potentially clearance of Fabry disease substrates Gb3 and lyso-Gb3. On Day 1, patients will be infused intravenously with a single dose of ST-920 and followed for a period of 52 weeks.
Conditions
- Fabry Disease
Interventions
ST-920Biological
Single dose of investigational product ST-920
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Treatment-emergent Adverse Events (TEAEs) - AllTime frame: Up to 12 months after the ST-920 infusion
- Incidence of Treatment-emergent Adverse Events (TEAEs) - Related to ST-920Time frame: Up to 12 months post ST-920 infusion
- Incidence of Treatment-emergent Adverse Events (TEAEs) - SeriousTime frame: Up to 12 month post ST-920 infusion
- Incidence of Treatment-emergent Adverse Events (TEAEs) - Any TEAEs Leading to Study Discontinuation or WithdrawalTime frame: Up to 12 month post ST-920 infusion
Locations
18 sites in 7 countries. Site status is shown where the registry gives one.
University of California, Irvine
Irvine, California
University of South Florida
Tampa, Florida
Emory University School of Medicine
Atlanta, Georgia
Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois
University of Iowa Hospital and Clinics
Iowa City, Iowa
University of Minnesota Medical Center
Minneapolis, Minnesota
Mt. Sinai School of Medicine
New York, New York
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio
Lysosomal and Rare Disorders Research and Treatment Center (LDRTC)
Fairfax, Virginia
The Royal Melbourne Hospital
Parkville, Victoria, Australia
M.A.G.I.C. Clinic Ltd.
Calgary, Alberta, Canada
University Medical Center Hamburg-Eppendorf
Hamburg, Germany
University Hospital of Würzburg
Würzburg, Germany
Azienda Ospedaliero-Universitaria Careggi
Florence, Tuscany, Italy
National Taiwan University Hospital
Taipei, Taiwan
Queen Elizabeth Hospital
Birmingham, United Kingdom
Addenbrooke's Hospital
Cambridge, United Kingdom
Royal Free Hospital
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.